3.24  0.14 (4.52%)		06-04 15:59
Open: 3.15 High: 3.25 Volume: 60,452		Pre. Close: 3.1 Low: 3.08 Market Cap: 28(M)

Short term
Mid term
Targets	6-month :	4.3	1-year :	5.02
Resists	First :	3.68	Second :	4.3
Pivot price	3.01
Supports	First :	2.99	Second :	2.56
MAs	MA(5) :	3.25	MA(20) :	3.03
	MA(100) :	4	MA(250) :	0
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	54.6	D(3) :	59.6
RSI	RSI(14): 55.5
52-week	High :	9.98	Low :	1.98

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ NSRX ] has closed below upper band by 23.7%. Bollinger Bands are 50.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.25 - 3.27	3.27 - 3.29
Low:	3.04 - 3.06	3.06 - 3.08
Close:	3.2 - 3.24	3.24 - 3.27

Nasus Pharma is a clinical-stage specialty pharmaceutical company focused primarily on the development of intranasal drugs to treat emergency medical conditions such as severe allergies, anaphylaxis, and opioid overdose. Their lead products include NS002, an intranasal powder epinephrine nasal spray for type 1 severe allergies and anaphylaxis, and NS001, an intranasal naloxone powder spray for opioid overdose. They use a powder-based intranasal technology that offers rapid drug absorption.

Mon, 01 Jun 2026
Number of shareholders of Nasus Pharma Ltd. – AMEX:NSRX - TradingView

Mon, 01 Jun 2026
Nasus Pharma to Host Virtual KOL Event on June 10, 2026 to Discuss NS002 for the Treatment of Anaphylaxis - The Manila Times

Mon, 01 Jun 2026
Needle-free epinephrine: Nasus KOL event on nasal anaphylaxis candidate - Stock Titan

Fri, 15 May 2026
Balyasny Group takes 9.99% position in Nasus Pharma Ltd (NSRX) - Stock Titan

Fri, 01 May 2026
Two New York investor events will feature Nasus Pharma CFO Eyal Rubin - Stock Titan

Fri, 01 May 2026
Nasus Pharma to Participate in Upcoming Investor Conferences - Yahoo Finance

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Shares Out	0 (M)
Shares Float	0 (M)
Held by Insiders	0 (%)
Held by Institutions	0 (%)
Shares Short	0 (K)
Shares Short P.Month	0 (K)

EPS	0
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	0 %
Return on Equity (ttm)	0 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	0 (M)
Levered Free Cash Flow	0 (M)

PE Ratio	0
PEG Ratio	0
Price to Book value	0
Price to Sales	0
Price to Cash Flow	0

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.